Hanall Biopharma Co (009420.KS) Stock Price
Hanall Biopharma Co Price
Revenue has compounded at 3.2% per year over the past 19 years to 155.18 B KRW. Earnings per share have grown at 10.6% per year over the last 17 years. Hanall Biopharma Co's net margin stands at -3.6%, down from 8.8% several years earlier. Hanall Biopharma Co currently offers a dividend yield of about 0.02%. The payout ratio is around 80% of earnings. Analysts set a median price target of 42,840.00 KRW, implying 6.8% above the current price. Of 10 analysts, 9 rate the stock a buy — an overall Buy consensus.
Hanall Biopharma Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Hanall Biopharma Co business model & stock analysis
Frequently asked questions about Hanall Biopharma Co
The business model of Hanall Biopharma Co Ltd is focused on the development and commercialization of innovative pharmaceutical products. As a leading biopharmaceutical company, Hanall Biopharma Co Ltd aims to discover, research, and manufacture high-quality drugs that address unmet medical needs. By leveraging advanced technologies and scientific expertise, the company strives to improve the health and well-being of patients worldwide. With a strong commitment to research and development, Hanall Biopharma Co Ltd consistently seeks new opportunities and collaborations to expand its product portfolio and deliver innovative solutions to the healthcare industry.
Hanall Biopharma Co Ltd is primarily active in the pharmaceutical industry.
Some of the main competitors of Hanall Biopharma Co Ltd in the market include companies like Celltrion Inc, Samsung Biologics Co Ltd, and Genexine Inc.
Hanall Biopharma Co Ltd is a leading biopharmaceutical company specializing in the development and commercialization of innovative medicines. Established in [insert year], Hanall Biopharma has a rich history in the biotechnology industry. The company is known for its strong focus on research and development, with a portfolio that includes [highlight key products/services]. Hanall Biopharma has achieved several milestones throughout its history, including [mention significant achievements]. With a commitment to improving patients' lives, Hanall Biopharma continues to drive advancements in the biopharmaceutical sector and is poised for continued success in the future.
Hanall Biopharma Co Ltd has achieved significant milestones in its journey. The company has successfully developed and commercialized various innovative pharmaceutical products, making a remarkable impact on the healthcare industry. Additionally, Hanall Biopharma Co Ltd has demonstrated consistent growth and expansion by establishing strategic partnerships, collaborations, and global presence. With its commitment to research and development, the company has achieved regulatory approvals for several groundbreaking medicines, enhancing treatment options and improving patient outcomes worldwide. Hanall Biopharma Co Ltd continues to strive for excellence, contributing to advancements in healthcare and solidifying its position as a leader in the pharmaceutical sector.
Hanall Biopharma Co Ltd is primarily present in South Korea.
Hanall Biopharma Co Ltd represents a strong commitment to innovation, quality, and patient-centricity. As a leading pharmaceutical company, Hanall Biopharma is dedicated to developing and commercializing innovative medicines that address unmet medical needs. The company's corporate philosophy revolves around scientific excellence, ethical business practices, and sustainable growth. Hanall Biopharma aims to improve patient outcomes through cutting-edge research and development, rigorous quality control, and global partnerships. With a focus on delivering high-value treatments, Hanall Biopharma continues to contribute to the advancement of healthcare and the well-being of patients worldwide.
Analysts currently set an average price target of 44,734.29 KRW for the Hanall Biopharma Co stock (median: 42,840.00 KRW), implying +11.6 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Hanall Biopharma Co stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Hanall Biopharma Co to generate revenue of 172.70 B KRW and earnings per share of -343.26 KRW.
Converted at the current exchange rate, the Hanall Biopharma Co share trades at 27.02 EUR (40,100.00 KRW).
The Hanall Biopharma Co share (009420.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (009420.KS).
Hanall Biopharma is a South Korean biotechnology company focused on manufacturing innovative drugs for the treatment of cancer and rare diseases. The company has a strong presence in the global market for biopharmaceuticals, with over 20 years of experience in the industry. Its business model is centered around research and development, manufacturing, and distribution. Hanall Biopharma invests a significant portion of its revenue in R&D for new drugs and is known for its expertise in developing biologically produced drugs using recombinant DNA technology. The company also specializes in the production of biopharmaceutical products, continuously improving manufacturing processes and technologies to meet international standards and regulations. Its product range includes a variety of biological drugs such as antibodies, vaccines, growth hormones, and enzymes. One of its flagship products is the cancer medication Welix, developed for the therapy of leukemia and lymphomas. Hanall Biopharma distributes its products in multiple countries, including South Korea, the USA, Europe, and China, through collaborations with distributors, healthcare organizations, and government agencies. The company also pursues strategic partnerships with other pharmaceutical companies to expand its development and distribution capabilities and explore new market opportunities. With its vision to improve people's health and well-being through innovative and effective drugs, Hanall Biopharma's continual investments in research and development, advanced technologies, and partnerships position it as a leading player in the biopharmaceutical industry.
The expected revenue of Hanall Biopharma Co is 172.70 B KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Hanall Biopharma Co is -17.57 B KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Hanall Biopharma Co is currently -116.82. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Hanall Biopharma Co stock.
The price-to-sales ratio (P/S) of Hanall Biopharma Co is currently 11.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Hanall Biopharma Co stock.
The Eulerpool Quality Score for Hanall Biopharma Co is 2/10.
The ISIN of Hanall Biopharma Co is KR7009420001. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Hanall Biopharma Co is 009420.KS. The ticker symbol is used to trade Hanall Biopharma Co shares on the stock exchange.
Hanall Biopharma Co stock
Hanall Biopharma Co Peer Group
Hanall Biopharma Co Ticker
Hanall Biopharma Co FIGI
All fundamentals and in-depth analysis of Hanall Biopharma Co
Our stock analysis for Hanall Biopharma Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hanall Biopharma Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.